A new collaborative development program aims to generate a novel imaging agent for use in the interventional oncology field.
Sirtex, a manufacturer of targeted liver cancer therapies, has announced a collaboration with Magle Chemoswed, a Sweden-based contract development and manufacturing organisation that serves companies in the pharmaceutical and medical device industry.
The development and commercial agreement will begin in the third quarter of 2020. Sirtex will have the exclusive license and commercialisation rights in the defined field of use, whilst Magle Chemoswed maintains rights to its technology platform and to exclusively manufacture the product for supply to Sirtex.
Justin Pierce, Magle Chemoswed’s CEO, said: “This is an incredibly exciting collaboration with a recognised global leader in the industry. Sirtex will be able to nimbly move the project from development to regulatory approvals and commercialization, and we look forward to working closely with their team for optimal success.”
Sirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer.
Kevin R. Smith, Chief Executive Officer of Sirtex, said: “Our partnership with Magle Chemoswed marks an important step in our company growth, portfolio expansion and investment in patient-centered care worldwide. We’re honored to utilise this technology platform to advance innovative therapies for patients.”
“We’re thrilled to begin the collaborative program with Magle Chemoswed to combine our resources and expertise,” said Mark Turco, Global Chief Medical Officer and EVP, Research and Development of Sirtex. “This technology will open the door to new product development opportunities for optimal patient care.”
Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer across 1,300 medical centers.